Zacks Research Issues Negative Forecast for COO Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Cooper Companies in a research report issued to clients and investors on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical device company will earn $0.93 per share for the quarter, down from their prior forecast of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

A number of other brokerages have also recently issued reports on COO. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Robert W. Baird dropped their price objective on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Citigroup decreased their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Wells Fargo & Company raised their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Finally, Morgan Stanley decreased their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $110.25.

Cooper Companies Stock Down 1.4 %

COO opened at $83.77 on Monday. The business has a 50 day simple moving average of $89.33 and a 200-day simple moving average of $97.21. Cooper Companies has a 12 month low of $77.05 and a 12 month high of $112.38. The stock has a market capitalization of $16.75 billion, a P/E ratio of 42.96, a P/E/G ratio of 2.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The business had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors have recently bought and sold shares of COO. Byrne Asset Management LLC acquired a new stake in Cooper Companies during the 4th quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in shares of Cooper Companies in the fourth quarter worth approximately $34,000. New Age Alpha Advisors LLC acquired a new stake in shares of Cooper Companies during the fourth quarter worth approximately $38,000. Covestor Ltd grew its position in Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC acquired a new position in Cooper Companies in the 4th quarter valued at approximately $49,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.